文献速递乳腺癌放疗

乳腺癌局限性区域复发累及内乳淋巴结的总生存分析

Overall Survival of Breast Cancer Patients With Locoregional Failures Involving Internal Mammary Nodes.
PubMed 文献 · Adv Radiat Oncol · 2019-03-01

该回顾性研究分析了553例复发乳腺癌患者中161例首次局限性区域复发者,其中67例(42%)存在内乳淋巴结受累。内乳淋巴结复发患者中位总生存为2.5年,与病变范围显著相关(P < .0001);合并远处转移、炎性乳腺癌和三阴性组织学类型与更差的总生存相关,而挽救性放疗与改善的总生存相关。

要点

  • 内乳淋巴结复发患者中位总生存为2.5年,与病变范围显著相关(P < .0001)。
  • 合并远处转移、炎性乳腺癌和三阴性组织学类型与更差的总生存相关。
  • 挽救性放疗与改善的总生存相关。

核心结论

  • 孤立性内乳淋巴结复发患者通过积极治疗可获得长期生存,挽救性放疗与改善的生存相关。

研究设计与样本

  • 回顾性分析553例复发乳腺癌患者,识别161例首次局限性区域复发且有影像学证据者,其中67例(42%)存在内乳淋巴结受累。

主要发现

  • 67例内乳淋巴结复发患者中,10例(15%)为孤立性复发,14例(21%)合并其他局限性区域病变,43例(64%)合并远处转移。
  • 内乳淋巴结复发患者中位总生存为2.5年,与病变范围显著相关(P < .0001)。
  • 多变量分析显示,合并远处转移、炎性乳腺癌和三阴性组织学类型与更差的总生存相关,挽救性放疗与改善的总生存相关。
  • 10例孤立性内乳淋巴结复发患者的中位无进展生存为6.0年,手术、放疗和化疗的挽救性治疗与最佳结局相关。

临床怎么用

  • 对于内乳淋巴结复发患者,应评估病变范围(是否合并远处转移等)以判断预后。
  • 挽救性放疗可能与改善的总生存相关,可考虑用于内乳淋巴结复发患者。
  • 孤立性内乳淋巴结复发患者可从手术、放疗和化疗的积极挽救性治疗中获益。

局限性

  • 本研究为回顾性分析,样本量有限,尤其孤立性内乳淋巴结复发患者仅10例。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Internal mammary node recurrence after definitive breast cancer treatment is poorly characterized, with limited data to guide clinical management. The aim of this study was to analyze the outcomes of patients with recurrent breast cancer involving internal mammary nodes to understand their natural history and determine prognostic factors associated with improved overall survival. METHODS AND MATERIALS: We performed a retrospective analysis of 553 patients with recurrent breast cancer and identified 161 patients with radiographic evidence of locoregional recurrence as a first event. A total of 67 patients (42%) were identified with internal mammary involvement. Median follow-up times were 76 months from date of initial diagnosis and 30 months from date of recurrence. RESULTS: Of the 67 patients identified with internal mammary node failures, 10 (15%) presented with isolated recurrence, 14 (21%) presented with other sites of locoregional disease, and 43 (64%) presented with concomitant distant metastases. Median overall survival was 2.5 years and significantly associated with extent of disease (P < .0001). On multivariable analysis, concomitant distant metastases, inflammatory breast cancer, and triple negative histologic type were associated with worse overall survival, whereas salvage radiation therapy was associated with improved overall survival. Among the 10 patients with isolated internal mammary node failures, median progression-free survival was 6.0 years and salvage therapy with surgery, radiation, and chemotherapy were associated with the best outcomes. CONCLUSIONS: Patients with isolated internal mammary node recurrences achieved long-term survival with aggressive therapies, and salvage radiation therapy was associated with improved survival.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Xu AJ, DeSelm CJ, Ho AY, et al. Overall Survival of Breast Cancer Patients With Locoregional Failures Involving Internal Mammary Nodes. Adv Radiat Oncol. 2019. PMID: 31360798. doi:10.1016/j.adro.2019.02.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。